IMMUNOGENICITY OF RECOMBINANT HEPATITIS B VACCINE

The Lancet

Volumn 325, Issue 8426, 1985, Pages 455-456

  Papaevangelou, G ^a   Dandolos, E ^a   Roumeliotou Karayannis, A ^a   Richardson, S C ^a  

^a National Centre for Viral Hepatitis   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INACTIVATED VIRUS VACCINE; RECOMBINANT DNA; VIRUS VACCINE;

DRUG EFFICACY; DRUG FORMULATION; DRUG THERAPY; EDITORIAL; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER; METHODOLOGY; NORMAL HUMAN; PREVENTION; PRIORITY JOURNAL; THERAPY; VIRUS RECOMBINANT;

ADOLESCENT; ADULT; ANTIBODY FORMATION; DNA, RECOMBINANT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; VIRAL VACCINES;

EID: 0021968486     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(85)91171-7     Document Type: Letter

References (4)

1. Clinical evaluation of a recombinant hepatitis B vaccine
2. Human hepatitis B vaccine from recombinant yeast
3. Safety and immunogenicity of a further reduced dose (10 µg) of the hepatitis B vaccine
4. Affinity of antibody responses in man to hepatitis B vaccine determined with synthetic peptides